Skin Supplements for Prevention: What the Evidence Shows

Most supplements marketed for skin health promise more than the evidence can pay for. The best current map of the field finds systematic review-level prevention evidence for three specific interventions: green tea catechins for UV-induced redness, nicotinamide for some older adults with a history of non-melanoma skin cancer, and certain probiotics for preventing eczema in early childhood. Oral collagen, vitamin C, zinc, and omega-3s did not have qualifying systematic-review evidence for preventing skin disease in disease-free people.

That conclusion comes from a 2026 umbrella review by Granvillano et al., which synthesized six systematic reviews and meta-analyses. An umbrella review sits above individual trials and ordinary systematic reviews: it asks which interventions have already accumulated enough evidence to survive a more demanding filter. It does not answer every version of "Is this good for skin?" It asks a narrower, more useful question: does systematic-review-level evidence show that an oral nutrient prevents a defined skin disease?

The answer is short enough to fit on a supplement label, though perhaps not one designed by a supplement company.

What the review actually found

The review identified green tea catechins, nicotinamide (also called niacinamide), and Lactobacillus rhamnosus, alone or paired with Bifidobacterium strains. Each intervention applied to a different outcome and population. Treating them as a general "skin stack" would blur the evidence beyond recognition.

• Green tea catechins were linked to prevention of UV-induced erythema, the skin redness produced by ultraviolet exposure.
• Nicotinamide was linked to lower basal cell carcinoma and squamous cell carcinoma risk in older adults with a prior history of non-melanoma skin cancer.
• Specific probiotic regimens were linked to lower incidence of atopic eczema in early childhood when given prenatally to mothers and/or postnatally to infants.

The review used the JBI Critical Appraisal Checklist and GRADE methods, but the available publication text does not provide the certainty rating for every included review. It also reports several findings with an ordinal scale rather than pooled risk ratios or confidence intervals. That limits precision. A consistent direction of effect is useful; it is not the same thing as knowing exactly how large the benefit is.

Green tea catechins: a signal for UV redness, not a sunscreen replacement

Green tea catechins had the broadest support for oral photoprotection. Two systematic reviews, covering 11 studies, found that oral catechin supplementation prevented UV erythema with a frequency rated "almost always" to "always" and an effect magnitude rated "moderate" to "strong" in the umbrella review. In that framework, "moderate" means an effect above 10% and "strong" above 25%.

Those categories describe the review's synthesis, not a pooled clinical effect estimate. The accessible text does not report the change in minimum erythema dose, confidence intervals, p-values, dose, or the minimum duration needed for benefit. Readers should resist filling those blanks with a cheerful guess.

The proposed mechanism is also less settled than the redness result. The review found no statistically significant pooled effect on prostaglandin E2 (PGE2) or 12-HETE, two inflammatory mediators often invoked to explain photoprotection. It also found no confirmed antioxidant protective effect on skin integrity, and the 12-HETE findings showed high heterogeneity. The erythema signal can still be real while the proposed mechanism remains uncertain. It simply does not justify claims that catechins reproduce sunscreen biology in a capsule.

UV radiation remains the main modifiable environmental driver of non-melanoma skin cancer, and established prevention relies on topical photoprotection. A review of systemic photoprotection places oral agents in an adjunctive role. No head-to-head comparison of catechin supplements against topical SPF was identified, so there is no basis for swapping sunscreen for green tea extract. Use sunscreen; if you choose catechins, regard them as an unquantified possible add-on for UV erythema rather than cancer prevention.

Nicotinamide: relevant for a high-risk clinical group

Nicotinamide has a more specific use case. The umbrella review identified one qualifying 2024 systematic review and described a moderate effect on basal cell carcinoma and squamous cell carcinoma risk that appeared "sometimes," meaning in 25% to 75% of studies. The population matters more than the marketing copy: these were older adults with prior non-melanoma skin cancer.

That is secondary prevention. It concerns people who have already had basal cell carcinoma or squamous cell carcinoma, not healthy adults trying to prevent a first skin cancer. A 2025 review of supplements for actinic keratosis and field cancerization, a 2026 skin-cancer chemoprevention review, and a review of preventive options for cutaneous tumors all place nicotinamide in this high-risk chemoprevention conversation.

They do not establish a broad supplement recommendation for the public. The evidence foundation here is thinner than for childhood eczema prevention: one qualifying systematic review, an effect that did not appear in every study, and no extractable pooled effect estimate or confidence interval in the available review description. Dose, duration, and the subgroups most likely to benefit need a clinician's judgment. Someone with prior non-melanoma skin cancer has a reasonable reason to discuss nicotinamide with a dermatologist. Someone without that history is ahead of the evidence.

Probiotics: the strongest case is early-life eczema prevention

The probiotic finding has the most repetition across evidence syntheses, but it is also the easiest to overgeneralize. Three meta-analyses included in the Granvillano review found preventive effects on atopic eczema incidence in early childhood. The intervention was L. rhamnosus alone or in combinations with Bifidobacterium, given during pregnancy to mothers and/or after birth to infants.

Sun et al.'s 2021 meta-analysis examined mixed Lactobacillus and Bifidobacterium strains in children younger than 3 years. A separate 2025 umbrella review by Zhong et al. also found support for probiotic prevention of atopic dermatitis in children. Agreement between independent higher-level reviews raises confidence that there is a real signal.

Still, "probiotics" is a category, not an intervention. Effects shown with L. rhamnosus-containing combinations cannot be assigned to every capsule with a probiotic logo and a refrigerated shipping box. The optimal strain combination, dose, and timing—prenatal, postnatal, or both—remain unsettled. The evidence also does not apply to adults seeking prevention or treatment of skin disease.

That distinction becomes clear in a 2021 randomized, double-blind, placebo-controlled trial of L. rhamnosus and L. casei. It enrolled children who already had atopic dermatitis and cow's milk protein allergy. That is a treatment-context study in an affected clinical population, not a prevention study in healthy infants. Same genus does not mean same question.

Why collagen and the usual suspects do not make this list

Oral collagen peptides, vitamin C, zinc, and omega-3 fatty acids had no qualifying systematic reviews showing primary prevention of skin disease in disease-free individuals. This does not prove that they are ineffective for every skin-related goal. Research on cosmetic appearance, nutrient deficiency, wound healing, or treatment of established disease answers different questions.

But a prevention claim needs prevention evidence. Mechanistic plausibility cannot substitute for disease outcomes, and cosmetic outcomes cannot substitute for lower disease incidence. If you take one of these supplements for another reason, this review does not tell you to stop. If you take it to prevent skin disease, it does tell you that the supporting evidence has not reached the standard applied here.

The practical verdict

For day-to-day prevention, topical sun protection remains the foundation because it directly addresses UV exposure. Green tea catechins have a consistent but incompletely quantified signal for reducing UV erythema and may be an adjunct, not an alternative. Nicotinamide belongs in a clinician-guided discussion for older adults with previous basal or squamous cell carcinoma. Specific L. rhamnosus and Bifidobacterium regimens merit discussion with a pediatric clinician for expectant families concerned about childhood atopic eczema.

The useful question is not whether a supplement sounds good for skin. It is whether it has been tested for the prevention outcome, in people like you, with a result that survives evidence review.

On that standard, the shelf is much less crowded than the advertisements suggest.